Related Experiment Video
Updated: Sep 18, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
Caroline Y Chen1, Charlene M Fares2, Daniel Sanghoon Shin3,4
1Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. cychen@mednet.ucla.edu.
Introduction:
Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC).
Case Presentation:
Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadjuvant setting with concurrent radiation, followed by resection. The patient remains disease-free 4 months after surgery.
Conclusion:
This case report suggests that osimertinib may be effective as neoadjuvant therapy in resectable stage III disease. Additionally, we provide a summary of previous case reports and ongoing clinical trials for neoadjuvant EGFR inhibition in stage III NSCLC patients.
Insights
Neoadjuvant osimertinib shows promise for resectable stage III non-small cell lung cancer (NSCLC). This treatment, combined with radiation, led to a disease-free outcome in one patient, suggesting potential efficacy in early-stage EGFR-mutated NSCLC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard for metastatic non-small cell lung cancer (NSCLC).
- Neoadjuvant therapy aims to shrink tumors before surgery, improving resectability and patient outcomes.
Observation:
- A case report details an African American patient with stage IIIA NSCLC.
- The patient received neoadjuvant osimertinib concurrently with radiation therapy, followed by surgical resection.
Findings:
- The patient remains disease-free 4 months post-surgery, indicating a positive response to neoadjuvant osimertinib.
- This suggests potential efficacy of osimertinib in the neoadjuvant setting for resectable stage III NSCLC.
Implications:
- Osimertinib may be a viable neoadjuvant option for select patients with resectable stage III NSCLC.
- Further research into neoadjuvant EGFR inhibition for stage III NSCLC is warranted, including review of existing case reports and clinical trials.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
